LJLili Jiang

Lili Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lili Jiang has a total of 92 co-authors. Here are the top co-authors by number of shared publications:

  • Hui Guo

    Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, No 157 West Fifth Road, Xi'an, Shaanxi, 710004, PR China

    4 shared publications
  • Mengjie Liu

    Phase I Clinical Trial Ward, The Second Affiliated Hospital of Xi’an, Jiaotong University, Xi’an, China

    3 shared publications
  • Kejun Nan

    Oncology Hospital, Xi’an International Medical Center, Xi’an, Shaanxi, China

    2 shared publications
  • Kejun Nan

    Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University

    2 shared publications
  • Mengjie Liu

    Department of Medical Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

    2 shared publications
  • Qianqian Guo

    Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1, Jianshe East Road, Zhengzhou, 450000, China

    2 shared publications

Latest Publications

  • USP14 promotes malignant pleural mesothelioma progression and suppresses autophagy by stabilizing the YAP1-TEAD4 axis

    by Yiyang Bai, Mengjie Liu, Shirong Zhang, Deli Tan, Yamin Zhang, Lili Jiang, Zhiping Ruan

  • Open Access

    Time to benefit of perioperative immunotherapy among patients with resectable non-small-cell lung cancer

    by Yongyan Lu, Wenming Bian, Xiaohui Jia, Jingyi Li, Mengjie Liu, Ying Zan, Xiaolan Fu, Zhiyan Liu, Lanxuan Huang, Chao Li, et al.

  • Open Access

    Impact of NSAID type, initiation timing, duration and dose on clinical outcomes of immunotherapy in NSCLC: a multicenter two-cohort study

    by Yanlin Li, Xiaohui Jia, Mengjie Liu, Zehui Zhu, Hui Qiao, Jun Jiang, Miao Li, Weihu Xia, Longwen Xu, Enyong Zhang, et al.

    Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used medications in non-small cell lung cancer (NSCLC). We comprehensively evaluated the effect of NSAID exposure patterns on immunotherapy outcomes, prostaglandin E2 (PGE2) and immune cells. Methods: This multicenter study employed both prospective and retrospective approaches for patient enrollment. Patients were included if they had advanced NSCLC, and were first-time users of immune checkpoint inhibitor (ICI). Endpoints included progression-free survival (PFS) and overall survival (OS). Serum and tumor tissue were collected in the prospective subset for PGE2 and immune cell assay. Results: A total of 1,748 patients were included, with 232 patients prospectively enrolled. After multivariable adjustment, NSAID use was independently associated with improved PFS (HR 0.72, 95% CI 0.58 to 0.91, p=0.0053) and OS (HR=0.76, 95% CI 0.58 to 0.98, p=0.0364). Benefit was observed for both before-ICI (HR 0.75, 95 % CI 0.57 to 0.99, p=0.0383) and after-ICI initiation (HR 0.63, 95% CI 0.43 to 0.92, p=0.0159). For aspirin, low-dose aspirin users had better PFS than non-users (HR 0.69, 95% CI 0.51 to 0.94, p=0.0191), especially when used at least 30 days (HR=0.69, 95% CI 0.48 to 0.99, p=0.0464). Among non-selective NSAIDs, only after-ICI initiation improved OS (HR=0.49, 95% CI 0.24 to 0.99, p=0.0458). Any-grade (57.8% vs 53.4%) and grade ≥3 adverse events (9.2% vs 9.8%) were comparable among NSAID users and non-users. Serum sample indicated that aspirin was associated with less PGE2, which was related to better outcomes. On immune cells, RNA-seq revealed a correlation between the cyclooxygenase-2 pathway and neutrophils. Biosample analysis further demonstrated that aspirin use was associated with decreased neutrophils in both circulation and tumor. Conclusions: Long-term low-dose aspirin enhanced immunotherapy efficacy in patients with advanced NSCLC. PGE2 and neutrophils represented potential biomarkers guiding NSAID-immunotherapy integration. Trial registration number: NCT05754983 .


  • Open Access

    StructSAM: structure-aware prompt adaptation for robust lung cancer lesion segmentation in CT

    by Mengjie Liu, Yuxin Yao, Jinyong Jia, Jiali Yao, Zhengze Huang, Ziyang Zeng, Guangjin Pu, Yan Wu, Yuqi Bai, Bin Wang, et al.

    Accurate delineation of lung lesions in computed tomography (CT) scans is critical for diagnosis, staging, and treatment planning, yet remains a challenging task. While foundation models like the Segment Anything Model (SAM) excel in natural images, they often falter in medical imaging due to low contrast, ambiguous boundaries, and a lack of 3D context. To address these limitations, we propose StructSAM, a structure-aware prompt adaptation framework designed for robust volumetric segmentation, with a primary focus on lung cancer. StructSAM injects anatomical priors into the prompt pathway, employs a 3D inter-slice aggregator for volumetric consistency, and leverages PEFT for scalability. Experiments on the LIDC-IDRI dataset demonstrate that StructSAM achieves state-of-the-art accuracy on lung nodule segmentation, outperforming both classical architectures and SAM-based adaptations. Crucially, extended cross-organ evaluations on KiTS19 and MSD Pancreas datasets reveal that StructSAM effectively generalizes to other anatomical structures, highlighting its robustness to domain shifts. These findings suggest that embedding structural priors into foundation models is a promising strategy toward generic, clinically reliable, and efficient medical image segmentation.


  • First-Line Chemotherapy Plus Immune Checkpoint Inhibitors or Bevacizumab in Advanced Non-Squamous Non-Small-Cell Lung Cancer without Egfr Mutations or Alk Fusions

    by Panpan Jiang, Luying Geng, Ziyang Mao, Qinyang Wang, Wenjuan Wang, Min Jiao, Yu Yao, Nanzheng Chen, Jia Zhang, Kejun Nan, et al.

    Aim: To compare the efficacy and safety of first-line chemotherapy (Chemo) plus immune checkpoint inhibitors (ICIs) or bevacizumab (Bev) in advanced non-squamous non-small-cell lung cancer without ... Plain language summary Chemotherapy plus immune checkpoint inhibitors and chemotherapy plus bevacizumab were both superior to traditional chemotherapy and were recommended as the first-line treatme...


  • Open Access

    Identification of a Five-Gene Signature for Predicting Survival in Malignant Pleural Mesothelioma Patients

    by Yiyang Bai, Xiao Wang, Jia Hou, Luying Geng, Xuan Liang, Zhiping Ruan, Hui Guo, Kejun Nan, Lili Jiang

    Malignant pleural mesothelioma (MPM), predominantly caused by asbestos exposure, is a highly aggressive cancer with poor prognosis. The staging systems currently used in clinics is inadequate in evaluating the prognosis of MPM. In this study, a five-gene signature was developed and enrolled into a prognostic risk score model by LASSO Cox regression analysis based on two expression profiling datasets (GSE2549 and GSE51024) from Gene Expression Omnibus (GEO). The five-gene signature was further validated using the Cancer Genome Atlas (TCGA) MPM dataset. Univariate and multivariate Cox analyses proved that the five-gene signature was an independent prognostic factor for MPM. The signature remained statistically significant upon stratification by Brigham stage, AJCC stage, gender, tumor size, and lymph node status. Time-dependent receiver operating characteristic (ROC) curve indicated good performance of our model in predicting 1- and 2-years overall survival in MPM patients. The C-index was 0.784 for GSE2549 and 0.753 for the TCGA dataset showing moderate predictive accuracy of our model. Furthermore, Gene Set Enrichment Analysis suggested that the five-gene signature was related to pathways resulting in MPM tumor progression. Together, we have established a five-gene signature significantly associated with prognosis in MPM patients. Hence, the five-genes signature may serve as a potentially useful prognostic tool for MPM patients.


  • Autophagy in the “inflammation-carcinogenesis” pathway of liver and HCC immunotherapy

    by Sizhe Yu, Yu Wang, Li Jing, F.X. Claret, Qing Li, Tao Tian, Xuan Liang, Zhiping Ruan, Lili Jiang, Yu Yao, et al.


  • Open Access

    In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non-small cell lung cancer cell lines

    by Min-Cong Wang, Xuan Liang, Zhi-Yan Liu, Jie Cui, Ying Liu, Li Jing, Li-Li Jiang, Jie-Qun Ma, Li-Li Han, Qian-Qian Guo, et al.

    The concurrent administration of chemotherapy and epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) has previously produced a negative interaction and failed to confer a survival benefit to non‑small cell lung cancer (NSCLC) patients compared with first‑line cytotoxic chemotherapy. The present study aimed to investigate the optimal schedule of the combined treatment of cisplatin/paclitaxel and icotinib in NSCLC cell lines and clarify the underlying mechanisms. HCC827, H1975, H1299 and A549 human NSCLC cell lines with wild‑type and mutant EGFR genes were used as in vitro models to define the differential effects of various schedules of cisplatin/paclitaxel with icotinib treatments on cell growth, proliferation, cell cycle distribution, apoptosis, and EGFR signaling pathway. Sequence‑dependent antiproliferative effects differed among the four NSCLC cell lines, and were not associated with EGFR mutation, constitutive expression levels of EGFR or downstream signaling molecules. The antiproliferative effect of cisplatin plus paclitaxel followed by icotinib was superior to that of cisplatin or paclitaxel followed by icotinib in the HCC827, H1975, H1299 and A549 cell lines, and induced more cell apoptosis and G0/G1 phase arrest. Cisplatin and paclitaxel significantly increased the expression of EGFR phosphorylation in the HCC827 cell line. However, only paclitaxel increased the expression of EGFR phosphorylation in the H1975 cell line. Cisplatin/paclitaxel followed by icotinib influenced the expression of p‑EGFR and p‑AKT, although the expression of p‑ERK1/2 remained unchanged. The results suggest that the optimal schedule of the combined treatment of cisplatin/paclitaxel and icotinib differed among the NSCLC cell lines. The results also provide molecular evidence to support clinical treatment strategies for NSCLC patients.


    • 1 May 2014
      • Vol. 34  (5) , 627-30

    [Starvation-induced autophagy in cultured non-small cell lung cancer cells].

    by Qianqian Guo, Zhiyan Liu, Lili Jiang, Tinghua Hu, DongFan Li, Ying Liu, Mengjie Liu, Xuan Liang, Kejun Nan

    To observe autophagy induced by starvation in non-small cell lung cancer A459 and 95D cells. A549 and 95D cells in logarithmic growth in 1640 medium were cultured in Earle's balanced salt solution (EBSS) for 0, 1, 2, 3, 4 or 5 h. Autophagosome formation in the cell culture was observed by MDC fluorescent staining, and the expression of microtubule-associated protein 1 light chain 3 (LC3) and Beclin1 in the cells were detected using Western blotting. Compared with the control cells, the cells with prolonged starvation showed increased MDC-positive cells and autophagosome formation. The expression of Beclin-1 and the LC3-II/LC3-I ratio also increased as the starvation prolonged, reaching the peak levels at 3 h and 4 h, respectively. Autophagy can be induced by starvation in A549 and 95D cells in correlation with the expression of autophagy-related proteins LC3 and Beclin-1. These cell models of nutritional deficiency-induced autophagy may allow for a better understanding of the role of autophagy in the development of non-small cell lung cancer.


    • 1 March 2011
      • Vol. 40  (2) , 169-75

    [Protective effect of intranasal cilostazol administration on chronic injury after cerebral ischemia in mice].

    by Qi Zhang, Yi-Lu Ye, Qing Li, Wei-Ping Zhang, Li-Li Jiang, Er-Qing Wei, Yue-Ping Yu

    To investigate the protective effect of cilostazol administrated intranasally on chronic injury after focal cerebral ischemia in mice. Focal cerebral ischemia in mice was induced by middle cerebral artery occlusion (MCAO). Cilostazol was administrated intranasally or intraperitoneally 1 h, 4 h and 7 h after the operation; then twice a day from the second day for 2 weeks. The neurological deficit scoring and the inclined board testing were performed within 35 d after ischemia. The survival rate, infarct volume and neuron density were assessed 35 d after ischemia. Intranasal cilostazol at 0.3 mg/kg increased the survival rate. Intranasal cilostazol (0.3 mg/kg, 1 mg/kg) and intraperitoneal cilostazol (10 mg/kg) significantly attenuated neurological deficit, reduced infarct volume, and increased the survival neuron density in the border of ischemia region. Cilostazol administered intranasally demonstrates protective effects on chronic cerebral ischemia in mice.